Literature DB >> 2461945

Addition of carbohydrate side chains at novel sites on influenza virus hemagglutinin can modulate the folding, transport, and activity of the molecule.

P Gallagher1, J Henneberry, I Wilson, J Sambrook, M J Gething.   

Abstract

We have constructed and expressed a series of mutant influenza virus hemagglutinins, each containing a new consensus site for glycosylation in addition to the seven sites found on the wild-type protein. Oligosaccharide side chains were added with high efficiency at four of the five novel sites, located on areas of the protein's surface that are not normally shielded by carbohydrate. Investigations of the structure, intracellular transport, and biological activities of the mutant hemagglutinin molecules indicated that (a) supernumerary carbohydrate side chains can be used to shield or disrupt functional epitopes on the surface of hemagglutinin, and (b) the presence of an additional oligosaccharide may cause temperature-dependent defects in the transport of the glycoprotein. We discuss the addition of supernumerary oligosaccharides as a general tool for shielding chosen areas of the surface of proteins that enter or traverse the secretory pathway.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2461945      PMCID: PMC2115654          DOI: 10.1083/jcb.107.6.2059

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   10.539


  42 in total

1.  Antibody-induced linkages of plasma membrane proteins to intracellular actomyosin-containing filaments in cultured fibroblasts.

Authors:  J F Ash; D Louvard; S J Singer
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

2.  The nonglycosylated glycoprotein of vesicular stomatitis virus is temperature-sensitive and undergoes intracellular aggregation at elevated temperatures.

Authors:  R Gibson; S Schlesinger; S Kornfeld
Journal:  J Biol Chem       Date:  1979-05-10       Impact factor: 5.157

3.  Cell-surface expression of a membrane-anchored form of the human chorionic gonadotropin alpha subunit.

Authors:  J L Guan; H Cao; J K Rose
Journal:  J Biol Chem       Date:  1988-04-15       Impact factor: 5.157

4.  Host cell- and virus strain-dependent differences in oligosaccharides of hemagglutinin glycoproteins of influenza A viruses.

Authors:  K Nakamura; R W Compans
Journal:  Virology       Date:  1979-05       Impact factor: 3.616

Review 5.  Inhibitors of the biosynthesis and processing of N-linked oligosaccharide chains.

Authors:  A D Elbein
Journal:  Annu Rev Biochem       Date:  1987       Impact factor: 23.643

Review 6.  The structure and function of the hemagglutinin membrane glycoprotein of influenza virus.

Authors:  D C Wiley; J J Skehel
Journal:  Annu Rev Biochem       Date:  1987       Impact factor: 23.643

7.  Influence of new glycosylation sites on expression of the vesicular stomatitis virus G protein at the plasma membrane.

Authors:  C E Machamer; J K Rose
Journal:  J Biol Chem       Date:  1988-04-25       Impact factor: 5.157

8.  Intracellular protein topogenesis.

Authors:  G Blobel
Journal:  Proc Natl Acad Sci U S A       Date:  1980-03       Impact factor: 11.205

9.  Vesicular stomatitis virus G proteins with altered glycosylation sites display temperature-sensitive intracellular transport and are subject to aberrant intermolecular disulfide bonding.

Authors:  C E Machamer; J K Rose
Journal:  J Biol Chem       Date:  1988-04-25       Impact factor: 5.157

10.  The role of the asparagine-linked oligosaccharides of the alpha subunit in the secretion and assembly of human chorionic gonadotrophin.

Authors:  M M Matzuk; I Boime
Journal:  J Cell Biol       Date:  1988-04       Impact factor: 10.539

View more
  37 in total

1.  Glycosylation requirements for intracellular transport and function of the hemagglutinin of influenza virus.

Authors:  P J Gallagher; J M Henneberry; J F Sambrook; M J Gething
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

Review 2.  Viral glycoprotein heterogeneity-enhancement of functional diversity.

Authors:  I T Schulze; I D Manger
Journal:  Glycoconj J       Date:  1992-04       Impact factor: 2.916

Review 3.  Functional aspects of glycoprotein N-linked oligosaccharide processing by human tumours.

Authors:  C S Foster
Journal:  Br J Cancer Suppl       Date:  1990-07

Review 4.  Membrane fusion of enveloped viruses: especially a matter of proteins.

Authors:  D Hoekstra
Journal:  J Bioenerg Biomembr       Date:  1990-04       Impact factor: 2.945

Review 5.  Glycomics and glycoproteomics of viruses: Mass spectrometry applications and insights toward structure-function relationships.

Authors:  John F Cipollo; Lisa M Parsons
Journal:  Mass Spectrom Rev       Date:  2020-04-29       Impact factor: 10.946

6.  Role of N-linked oligosaccharides in processing and intracellular transport of E2 glycoprotein of rubella virus.

Authors:  Z Qiu; T C Hobman; H L McDonald; N O Seto; S Gillam
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

7.  Addition of N-glycans in the stalk of the Newcastle disease virus HN protein blocks its interaction with the F protein and prevents fusion.

Authors:  Vanessa R Melanson; Ronald M Iorio
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

8.  Role of conserved glycosylation sites in maturation and transport of influenza A virus hemagglutinin.

Authors:  P C Roberts; W Garten; H D Klenk
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

9.  Effect of the addition of oligosaccharides on the biological activities and antigenicity of influenza A/H3N2 virus hemagglutinin.

Authors:  Yasuhiro Abe; Emi Takashita; Kanetsu Sugawara; Yoko Matsuzaki; Yasushi Muraki; Seiji Hongo
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

10.  Predicting the antigenic structure of the pandemic (H1N1) 2009 influenza virus hemagglutinin.

Authors:  Manabu Igarashi; Kimihito Ito; Reiko Yoshida; Daisuke Tomabechi; Hiroshi Kida; Ayato Takada
Journal:  PLoS One       Date:  2010-01-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.